LONDON (Reuters) -Zealand Pharma is considering a direct-to-patient sales model for its experimental weight-loss drug alongside traditional insurer channels, its CEO told Reuters in an interview on Monday, citing shifting dynamics in the booming obesity drug market.
(Reporting by Maggie Fick; Editing by Jan Harvey)
Brought to you by www.srnnews.com
